GGTI-298 TFA

Overview
Catalog #	bs-7026c-10mg-solid
Product Name	GGTI-298 TFA
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 593.66 Formula: C29 H34 F3 N3 O5 S CAS Number: 1217457-86-7 InChi Key: MNGYFSSTNSEPNF-UFABNHQSSA-N InChi: InChI=1S/C27H33N3O3S.C2HF3O2/c1-17(2)13-25(27(32)33)30(3)26(31)23-12-11-20(29-15-19(28)16-34)14-24(23)22-10-6-8-18-7-4-5-9-21(18)22;3-2(4,5)1(6)7/h4-12,14,17,19,25,29,34H,13,15-16,28H2,1-3H3,(H,32,33);(H,6,7)/t19-,25+;/m1./s1 Smiles: CC(C)C[C@@H](C(O)=O)N(C)C(=O)C1C=CC(=CC=1C1=CC=CC2=CC=CC=C21)NC[C@@H](N)CS.OC(=O)C(F)(F)F Purity: 98.0 Solubility: Soluble in DMSO Appearance: Solid Power. Shelf Life: 1.0 years
Description	GGTI-298 is a potent geranylgeranyltransferase-I (GGTase-I) inhibitor with potential antitumor actrivity. GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.